JNJ · Johnson & Johnson
AI read · Good for JNJ
The AI's read
The new use gives the medicine access to another group of patients, which may widen its sales opportunity. Eligibility is limited to patients whose cancer progressed after platinum chemotherapy and anti-PD-(L)1 treatment. HPV-associated oropharyngeal cancer is excluded, but the added approved use supports a positive read for Johnson & Johnson.